Drug Search Results
More Filters [+]

Somapacitan

Alternative Names: somapacitan, nnc0195-0092, somapacitan-beco, sogroya
Latest Update: 2024-10-11
Latest Update Note: Clinical Trial Update

Product Description

Somapacitan is a long-acting, reversible albumin-binding GH derivative in development for once-weekly administration in patients with growth hormone deficiency (GHD). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31917835/)

Mechanisms of Action: Growth Hormone Analogue

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Latvia | Lithuania | Netherlands | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | Sweden | Taiwan | United States

Approved Indications: None

Known Adverse Events: None

Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Somapacitan

Countries in Clinic: Algeria, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Russia, Saudi Arabia, Serbia, Slovenia, South Africa, Spain, Switzerland, Thailand, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 15

Highest Development Phases

Phase 3: Dwarfism, Pituitary|Gonadal Dysgenesis|Hypopituitarism|Noonan Syndrome|Turner Syndrome

Phase 2: Dwarfism|Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NN8640-4467

P3

Unknown Status

Noonan Syndrome|Turner Syndrome

2027-06-16

NN8640-4469

P3

Unknown Status

Turner Syndrome|Noonan Syndrome

2027-03-18

2021-005607-13

P3

Active, not recruiting

Noonan Syndrome|Turner Syndrome

2026-07-09

NN8640-4263

P3

Unknown Status

Hypopituitarism

2025-09-30

Recent News Events